GASTROESOPHAGEAL REFLUX DISEASE AND BRONCHIAL ASTHMA: MECHANISMS OF COMORBID FORMATION AND COURSE. by Oparin, Aleksey et al.
Original Research Article:
full paper




GASTROESOPHAGEAL REFLUX DISEASE AND 







1Department of Therapy, Rheumatology and Clinical Pharmacology
2Kharkiv Medical Academy of Postgraduate Education
58 Amosova str., Kharkiv, Ukraine, 61176
Abstract
The aim of the study: To estimate the level of Galectin-3 with the parallel tracing of the content of pro- and anti-inflammatory 
cytokines Interleukin-6 (IL-6) and Interleukin-4 (IL-4) for patients with GERD and BA both in case of separate nosologies, and in case 
of their combined course during the period of exacerbation of the diseases.
Methods. The study was conducted in three groups of patients, homogeneous by gender and age. The first group included 
18 patients with GERD. The second group included 19 patients with intermittent or persistent-mild bronchial asthma. The third group 
included 22 patients suffering from GERD with concomitant BA intermittent or persistent-mild severity. Determination of the level of 
galectin-3 and interleukins (IL-4 and IL-6) in the blood serum was carried out by enzyme-linked immunosorbent assay.
Results. Analyzing the results of the study, we found that the level of galectin - 3 was increased on average in both groups of 
patients with isolated GERD (and in patients with BA). In patients of the third group with comorbid pathology, the level of galectin-3 was 
statistically significantly higher than not only the norm, but also the average of patients with isolated BA and GERD. At the same time, 
we found the rise in the level of pro-inflammatory (IL-6) and anti-inflammatory (IL-4) cytokines. Moreover, in patients with GERD, 
the level of IL-6 was increased with a higher degree of reliability, and the level of IL-4 was increased with a lower degree of reliability. 
In patients with BA, on the contrary, the level of IL-4 was determined more often and higher, and the level of IL-6 was lower.
Conclusions. Analyzing result of the study, a clear correlation and features of changes in the level of galectin-3, IL-4, IL-6 in 
patients with isolated GERD, BA, as well as with the comorbidity of these diseases, were revealed.
In patients with BA, the level of galectin-3 increases with the same degree of certainty as in the group of patients with GERD. In 
the cytokine system, on the contrary, the level of anti-inflammatory (IL-4) cytokines increases with a greater degree of certainty than 
the level of pro-inflammatory (IL-6) cytokines.
In patients with GERD with concomitant BA, the level of galectin-3 increases with a greater degree of certainty. It is observed 
also a higher rising of pro-inflammatory (IL-6) cytokines and a slightly pronounced increasing of the level of anti-inflammatory (IL-4) 
cytokines in comparison with the group of patients with isolated GERD.
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1. Introduction
The comorbid course of diseases has become the subject of numerous studies of modern 
medicine [1, 2]. Particular attention is paid to a deeper learning of the general pathogenetic mech-
anisms, to the clinical picture, which can significantly change within several concurrent diseases 
[3, 4]. In recent years, special attention has been paid to galectin-3 and its role in the development 
of numerous physiological and pathological processes [5–7]. Galectin-3 is one of the representa-
tives of the 5-lectin family, that influences intercellular interaction, cell growth, regulation of the 
cell cycle, apoptosis and, in particular, the nature and the course of inflammatory mechanisms, 
which violation is one of the key factors in the formation of many diseases of the internal organ 
systems, including the bronchopulmonary and digestive systems [8, 9].
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This problem, associated with the process (mechanism) of systemic inflammation, is of par-
ticular importance for patients suffered from gastroesophageal reflux disease (GERD) and bron-
chial asthma (BA) [10, 11]. With the increasing prevalence of BA symptoms among patients with 
GERD the mutual aggravating effect of these diseases, and as a result an increase in the number of 
severe forms and the development of combined pathologies is observed [12–14].
However, many issues in regard to the depth and nature of the cytokine system disorder and, 
especially, to the level of galectin-3 in the development of the GERD/BA, and their comorbidity, 
have been remaining completely unresolved and require further research [15–17].
The aim of the study. To estimate the level of galectin-3 with the parallel tracing of the 
content of pro- and anti-inflammatory cytokines Interleukin-6 (IL-6) and Interleukin-4 (IL-4) for 
patients with GERD and BA both in case of separate nosologies, and in case of their combined 
course during the period of exacerbation of the diseases.
2. Materials and methods
Studies were conducted in 2016, 2017 years on the base of Kharkiv state medical hospitals 
No. 13 and No. 20 in three groups of patients, homogeneous by gender and age. The first group 
included 18 patients (10 men and 8 women) in age of 18 to 45 years (average age 24.4±2.3) with 
gastroesophageal reflux disease. 15 patients had a non-erosive form, and three patients had an ero-
sive form of GERD. The second group included 19 patients with intermittent and persistent-mild 
bronchial asthma. Among them were 12 men and 7 women, age range was 19 to 38 years (average 
age 25.1±2.96). The third group included 22 patients (14 men and 8 women) in age of 18 to 36 years 
(average age 25.2±2.10), that were suffering from erosive GERD (5 patients), and a non-erosive 
GERD (17 patients) with concomitant intermittent or persistent-mild bronchial asthma.
The diagnosis of GERD was made according to ICD-10, the Montreal Consensus (2006), 
questionnaire data, that was developed at the “Therapy National Institute named after L. T. Malaya 
of the National Academy of Medical Sciences of Ukraine” (application 2625 from July 4, 2008), the 
results of esophagogastroduodenoscopy, fluoroscopy of the esophagus and stomach, as well as the 
results of pH measurement.
The diagnosis of asthma was verified in accordance with the recommendations of WHO 
(GINA), ICD-10 by the order of the Ministry of Health of Ukraine No. 868 (08.10. 2013), taking 
into account the results of spirography and radiography of the chest organs. Exclusion criteria were 
other organic diseases in patients (including the digestive and respiratory systems), severe BA, and 
refusal of patients to participate in the study.
Determining the level of galectin-3 in the blood was carried out by an enzyme-linked im-
munosorbent assay using the Human galectin-3 platinum ELISA reagent kit, manufactured by Bio-
science (Austria). The level of interleukins in the blood serum was determined by the method of 
immuno-enzyme analysis using test systems “Vector Best”. Average values of 20 healthy individ-
uals of the control group of the same age and gender were taken as normal.
Statistical processing was carried out by the method of variation statistics using the standard 
software Statistica 6.0 with calculation of arithmetic mean values: M, m. The difference was evalu-
ated by the by Student’s t-test. The difference was considered as significant at p<0.05. To build-up 
the relationship between the indicators, a correlation analysis was used with the calculation of the 
correlation coefficient (r) and estimating of its reliability.
3. Results
In the course of the study, we found that in patients with GERD and BA and in patients with 
comorbidity of these diseases, are developing the typical for each group of the patients’ changes in 
blood levels of galectin-3 and cytokines – IL-4 and IL-6. In particular, the level of galectin-3 was 
increased on average both in patients with isolated GERD (up to 11.15±1.05 ng/ml) at normal rates 
(5.61±0.79 ng/ml) and in patients with BA – (up to 11.90±1.27 ng/ml). When compared to normal, 
the difference in both the first and second groups of patients was equally statistically significant 
(p<0.001). In patients of the third group with comorbid pathology, the level of galectin-3 was much 
higher and on average its level (16.41±1.76 ng/ml) was statistically significantly higher not only 
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than normal values (p<0.001), but also average values of patients with isolated BA (p<0.05) and 
GERD (p <0.05). 
At the same time, in these patients we found an increase in the level of pro-inflammatory 
(IL-6) and anti-inflammatory (IL-4) cytokines. Moreover, in patients with GERD with a high-
er degree of certainty, the level of IL-6 was increased (up to 9.70±0.65 pg/ml) at normal rates 
(5.33±0.58 pg/ml) and the level of IL-4 increased with a lower degree of certainty – up to 2.70±0.11 
with a normal of 1.71±0.21 pg/ml. (Table 1).
Table 1
The level of galectin-3 and cytokines in the blood of patients with GERD, AD and their comorbidity and 
healthy individuals in the control group.
Indices
Patients
Control group  




GERD and concomitant BA 
n=22
Galectin – 3 ng/ml 11.15±1.05 11.9±1.27 16.41±1.76 5.61±0.79 p<0.001
IL-4 pg/ml 2.70±0.11 3.82±0.35 2.75±0.22 1.71±0.21 p<0.001
IL-6 pg/ml 9.70±0.65 7.21±0.56 11.90±0.86 5.33±0.58 p<0.001







Note: p – confidence level
In patients with BA, on the contrary, the level of IL-6 (up to 7.21±0.56 pg/ml) was lower 
and the level of IL-4 (up to 3.82±0.35 pg/ml) was higher. In BA patients, the average level of 
IL-4 in relation to the normal value (p<0.001) and in relation to the average index of the group of 
GERD-patients (p<0.05) was statistically significantly higher. The average level of IL-6 in relation 
to the normal value was statistically significantly higher too (p<0.05), but in relation to the average 
index of the group of GERD-patients – statistically significantly lower (p<0.001) (Table 1).
In patients of the third group with comorbid pathology, the level of IL-6 increased up 
to 11.90±0.86 pg/ml, that was statistically significantly higher (p<0.001) in relation to the nor-
mal value and to the average indexes of patients with isolated GERD and BA. The average 
level of IL-4 (2.75±0.22 pg/ml) was, on the contrary, statistically significantly lower than in 
patients with BA (3.82±0.35 pg/ml), but remained statistically significantly higher (p<0.01), than 
in the group of healthy individuals, as well as patients with GERD without a combined patholo- 
gy (p<0.05); Table 1.
4. Discussion
These facts are clearly showing that in patients with an exacerbation of the disease, not only 
the level of cytokines increases, but also an imbalance arises, i. e. the ratio of pro- and anti-inflam-
matory cytokines IL-6/IL-4 changes. It decreases to 1.88 while a norm of 3.11 in BA patients and 
increases to 4.15 and 4.33 in patients with GERD and comorbidity respectively (p<0.001); Table 1. 
According to recent studies, it is believed that chronic aspiration associated with gastroesopha-
geal reflux disease (GERD) plays a significant role in the development of asthma [11, 16, 18–20]. 
Experimental observations of the relationship between aspiration and asthma obtained during ep-
idemiological studies show that between 50 and 90 % of people with asthma suffering from some 
symptoms of GERD. It was proved [19] that as a result of the reflux-induced airway hypersensitiv-
ity, a tendency is observed to decrease the production of IgG anti-ovalbumin, IgE anti-ovalbumin 
and total IgE. In addition, aspiration induces a significant increase of the anti-ovalbumin ratio 
IgG1/IgG2a, that is consistent with a shift towards a predominantly Th2 response.
According to [18, 19], the urgency of this problem is also due to the fact that the etiology and 
pathogenesis of GERD and BA are different, but they have a common component – inflammation 
with impaired immune responses in the form of an imbalance between cellular (ThI) and humo- 
ral (Th2) one. Response cells can acquire either a pro-inflammatory (M1) or alternatively anti- 
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inflammatory (M2) phenotype [21, 22], depending on many factors and first of all on the preva-
lence of cytokine levels [11, 18].
In unison with other researcher [18], who were monitoring the level of other pro-inflamma-
tory (IL-1β, IL-8, IL-12) and anti-inflammatory (IL-5, IL-10) cytokines and their correlation, we 
have established that the level of alveolar macrophages in BA patients shifts toward the predomi-
nance of anti-inflammatory cytokines, and in GERD-patients – mainly towards pro-inflammatory 
cytokines. In patients with a combined pathology, it is seen a higher rise of M1 phenotype markers 
(p<0.05) and, to a lesser extent – of M2 phenotype (p<0.05). 
But we have first found up the role and place of galectin-3 in the mechanisms of the co-
morbid course of GERD and BA. Our data clearly indicates an increase in the level of galectin-3 
and an imbalance in simultaneously characteristic for each pathology system of pro- and anti-in-
flammatory cytokines (IL-4, IL-6) for each of these diseases during exacerbation. The identified 
changes of the studied parameters and their close correlation (p<0.05, r=0.47) are additionally 
confirming that the systemic inflammation occupies a central place in the mechanisms of for-
mation of the pathologies under consideration – whether GERD, BA or their combination and at 
the same time, indicates the need for a differentiated approach to the prevention and medication 
of such patients.
Study limitations. The study was not conducted in case of identified concomitant patholo-
gy of another organs and in case of patients refuse to participate in the study.
Prospects for further research. Determination of the level of galectin-3 and the content 
of pro- and anti-inflammatory cytokines (IL-4, IL-6) in patients with GERD and BA, as well as 
their comorbidity, indicate the advisability of studying them with the aim of diagnosing the dis-
ease at an earlier stages of their development and timely appointment of an adequate medication 
method of therapy.
4. Conclusions
In patients with GERD, the activity of systemic inflammation increases, as evidenced by 
a statistically significant increasing of the content of galectin-3 and an imbalance in the cytokine 
system with the highest rise of pro-inflammatory (IL-6) cytokines compared to the level of anti-in-
flammatory (IL-4) cytokines.
In patients with BA, the level of galectin-3 increases with the same degree of certainty as in 
the group of patients with GERD. In the cytokine system, on the contrary, the level of anti-inflam-
matory (IL-4) cytokines increases with a greater degree of certainty than the level of pro-inflam-
matory (IL-6) cytokines.
In patients with GERD with concomitant BA, the level of galectin-3 increases with a greater 
degree of certainty. It is observed also a higher rising of pro-inflammatory (IL-6) cytokines and a 
slightly pronounced increasing of the level of anti-inflammatory (IL-4) cytokines in comparison 
with the group of patients with isolated GERD.
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